Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases
- 12 February 2020
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 151 (1) , 75-84
Abstract
Aim Brain metastases traditionally carried a poor prognosis with treatment being a combination of surgery, whole-brain radiation therapy, and glucocorticoids; however, this treatment paradigm carried a significant amount of morbidity. In recent years, stereotactic radiosurgery (SRS), which involves the delivery of a highly conformal dose of radiation over a single session, has been shown to be an effective alternative to WBRT with excellent rates of local control and improved quality of life; however, a survival benefit has not been demonstrated. Recent developments have challenged the traditional view of the central nervous system being “immunologically privileged” which has led to a greater focus on treating these patients with systemic therapies. Immune checkpoint inhibitors (ICI) have been shown to improve survival in multiple malignancies. As a result, there has been increased utilization in combining these therapies in this setting. Methods We conducted a literature search of medical databases (e.g. PubMed) for articles involving the use of immune checkpoint inhibitors and stereotactic radiosurgery in managing brain metastases. Results Published evidence utilizing SRS and ICI is largely limited to single institution and retrospective in nature with the most common histology being melanoma. Conclusion Combination therapy with SRS and ICI appears to improve survival in patients with brain metastases. The available data are largely retrospective; therefore, ongoing and planned prospective studies are needed to further validate these findings.Keywords
This publication has 61 references indexed in Scilit:
- Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous SystemJNCI: Journal of the National Cancer Institute, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Adjuvant whole-brain radiation therapy after surgical resection of single brain metastasesNeuro-Oncology, 2010
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- CNS immune privilege: hiding in plain sightImmunological Reviews, 2006
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology groupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1980